Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rik C Schoemaker

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
BMC Clinical Pharmacology|January 10, 2006
Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilatDavid G Levitt, Rik C Schoemaker
Journal of Pharmacokinetics and Pharmacodynamics|October 4, 2002
Modeling the influence of growth hormone on lipolysisRik C Schoemaker, Madelon M Buijs, Hanno Pijl, et al.
Therapeutic Drug Monitoring|May 22, 2002
NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonatesMatthijs de Hoog, Rik C Schoemaker, John N van den Anker, et al.
Clinical Pharmacokinetics|October 18, 2002
The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarinRichard A Faaij, Jacobus Burggraaf, Rik C Schoemaker, et al.
British Journal of Clinical Pharmacology|December 21, 2002
Quantification of heparin-induced TFPI release: a maximum release at low heparin doseMichiel J B Kemme, Jacobus Burggraaf, Rik C Schoemaker, et al.
Pulmonary Pharmacology & Therapeutics|February 15, 2005
Relationship between airway responsiveness to neurokinin A and methacholine in asthmaJudith Cohen, Jacobus Burggraaf, Rik C Schoemaker, et al.
Clinical Pharmacology and Therapeutics|May 16, 2002
Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoringMatthijs de Hoog, Johan W Mouton, Rik C Schoemaker, et al.
Clinical Pharmacology and Therapeutics|October 19, 2002
Development of an optimal furosemide infusion strategy in infants with modeling and simulationRik C Schoemaker, Maria M j van dDer Vorst, Isabelle Ruijs-Dudok van Heel, et al.
British Journal of Clinical Pharmacology|June 20, 2003
Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertensionMichiel J B Kemme, Jeroen P vd Post, Rik C Schoemaker, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 13, 2003
Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory modelMichiel J Kemme, Rik C Schoemaker, Jacobus Burggraaf, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
BMC Clinical Pharmacology|January 10, 2006
Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilatDavid G Levitt, Rik C Schoemaker
Journal of Pharmacokinetics and Pharmacodynamics|October 4, 2002
Modeling the influence of growth hormone on lipolysisRik C Schoemaker, Madelon M Buijs, Hanno Pijl, et al.
Therapeutic Drug Monitoring|May 22, 2002
NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonatesMatthijs de Hoog, Rik C Schoemaker, John N van den Anker, et al.
Clinical Pharmacokinetics|October 18, 2002
The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarinRichard A Faaij, Jacobus Burggraaf, Rik C Schoemaker, et al.
British Journal of Clinical Pharmacology|December 21, 2002
Quantification of heparin-induced TFPI release: a maximum release at low heparin doseMichiel J B Kemme, Jacobus Burggraaf, Rik C Schoemaker, et al.
Pulmonary Pharmacology & Therapeutics|February 15, 2005
Relationship between airway responsiveness to neurokinin A and methacholine in asthmaJudith Cohen, Jacobus Burggraaf, Rik C Schoemaker, et al.
Clinical Pharmacology and Therapeutics|May 16, 2002
Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoringMatthijs de Hoog, Johan W Mouton, Rik C Schoemaker, et al.
Clinical Pharmacology and Therapeutics|October 19, 2002
Development of an optimal furosemide infusion strategy in infants with modeling and simulationRik C Schoemaker, Maria M j van dDer Vorst, Isabelle Ruijs-Dudok van Heel, et al.
British Journal of Clinical Pharmacology|June 20, 2003
Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertensionMichiel J B Kemme, Jeroen P vd Post, Rik C Schoemaker, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 13, 2003
Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory modelMichiel J Kemme, Rik C Schoemaker, Jacobus Burggraaf, et al.
Pageof 3